百诚医药：BIOS2242口服溶液获批临床试验

Core Viewpoint - Baicheng Pharmaceutical's subsidiary, Saimo Pharmaceutical, has received clinical trial approval from the National Medical Products Administration for its drug BIOS2242 oral solution, aimed at treating mild to moderate acute ischemic stroke [1] Group 1 - The drug BIOS2242 is specifically indicated for the treatment of mild to moderate acute ischemic stroke [1] - The approval allows the company to commence clinical trials for this new treatment [1]